Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREBLIN study of prophylactic tenofovir in rituximab-treated hematological cancer patients with resolved hepatitis B
2011-000905-30Phase 4Completed
- Sponsor
- Rafael Esteban Mur
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir disoproxil fumarate in Hepatitis B reactivation (HBVr) (2 arms), sponsored by Rafael Esteban Mur. Primary endpoint: Proportion of patients with HBV reactivation after 18 months. Started Jan 2012; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
Hepatitis B reactivation (HBVr)
Beyond the preview
Go deeper on 2011-000905-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000905-30.